1 **The future of computational pathology: expectations regarding the anticipated role of** 2 **artificial intelligence in pathology by 2030**

5 *Running Title: AI in pathology in 2030*

M Alvaro Berbís^{1,2,*} David S. McClintock³, Andrey Bychkov⁴, Jerome Y Cheng⁵, Brett Delahunt⁶, Lars Egevad⁷, Catarina Eloy⁸, 9 Alton B Farris III⁹, Filippo Fraggetta¹⁰, Raimundo García del Moral¹¹, Douglas J. Hartman¹², Markus D Herrmann¹³, Eva 10 Hollemans¹⁴, Kenneth A Iczkowski¹⁵, Aly Karsan¹⁶, Mark Kriegsmann¹⁷, Jochen K Lennerz^{18,} Liron Pantanowitz¹⁹, Mohamed E. 11 Salama²⁰, John Sinard²¹, Mark Tuthill²², Jeroen Van der Laak²³, Bethany Williams²⁴, César Casado-Sánchez^{25,2}, Víctor 12 Sánchez-Turrión^{26,2}, Antonio Luna²⁷, José Aneiros-Fernández^{1,11}, Jeanne Shen^{28,*}

-
-
- ³ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
- ⁴ Department of Pathology, Kameda Medical Center, Chiba, Japan
- ⁵ University of Michigan, Ann Arbor, MI, USA
- ⁶ Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand ⁷ Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
-
- ⁸ Pathology Laboratory, Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
⁹ Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
-
- ¹⁰ Pathology Unit, Azienda Sanitaria Provinciale Catania, Gravina Hospital, Caltagirone, Italy
- ¹¹ Department of Pathology, San Cecilio Clinical University Hospital, Granada, Spain
- 12 Department of Anatomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- ¹³ Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- ¹⁴ Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands
- ¹⁵ Department of Pathology, Medical College of Wisconsin, Milwaukee, USA
- 15 ¹ Department of Rathology, Kamel and Dios Hospital, Córdoba, Spain
16 ² Faculty of Medicine, Autonomous University of Madrid, Nadrid, Spain
⁴ Department of Laboratory Medicine and Pathology, Kayo Clinic, Rochester ¹⁶ Department of Pathology & Laboratory Medicine, University of British Columbia, Michael Smith Genome Sciences Centre,
Vancouver, Canada
- ¹⁷ Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
- ¹⁸ Department of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
- ¹⁹ Department of Pathology, University of Michigan, Ann Arbor, MI, USA
- 36 ²⁰ Department of Pathology, Sonic Healthcare, Austin, TX, USA
- 37 ²¹ Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
	- ²² Department of Medical Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK
- ²³ Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
- ²⁴ Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- ²⁵ Department of Plastic and Reconstructive Surgery, La Paz University Hospital, Madrid, Spain.
- ²⁶ Department of General Surgery and Digestive Tract, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain
- ²⁷ Department of Integrated Diagnostics, HT Médica, Clínica Las Nieves, Jaén, Spain
- 44 ²⁸ Department of Pathology and Center for Artificial Intelligence in Medicine & Imaging, Stanford University School of Medicine, 45 Stanford, CA, USA Stanford, CA, USA

46 47 49

- 51 Department of R&D, HT Médica, San Juan de Dios Hospital, Córdoba 14011, Spain
- 52 Faculty of Medicine, Autonomous University of Madrid, Madrid 28029, Spain
- a.berbis@htime.org 54

M Alvaro Berbís

48 **(*) Corresponding authors:**

- Jeanne Shen
- Department of Pathology and Center for Artificial Intelligence in Medicine & Imaging
- Stanford University School of Medicine, Stanford, CA 94305, United States of America
- jeannes@stanford.edu 59

 Keywords: Artificial intelligence; machine learning; digital pathology; computational pathology; anatomic pathology; pathologist workflow

ABSTRACT

 Background: Artificial intelligence (AI) is rapidly fueling a fundamental transformation in the practice of pathology. However, AI's clinical integration remains challenging, with no AI algorithms to date enjoying routine adoption within typical anatomic pathology (AP) laboratories. This survey gathered current expert perspectives and expectations regarding the role of AI in AP from those with first-hand

- computational pathology and AI experience.
- **Methods**: Perspectives were solicited using the Delphi method from 24 subject matter experts between
- December 2020 and February 2021 regarding the anticipated role of AI in pathology by the year 2030.
- The study consisted of three consecutive rounds: 1) an open-ended, free response questionnaire
- generating a list of survey items; 2) a Likert-scale survey scored by experts and analyzed for
- consensus; and 3) a repeat survey of items not reaching consensus to obtain further expert consensus.
- **Findings**: Consensus opinions were reached on 141 of 180 survey items (78.3%). Experts agreed that
- AI would be routinely and impactfully used within AP laboratory and pathologist clinical workflows by
- 2030. High consensus was reached on 100 items across nine categories encompassing the impact of
- AI on (1) pathology key performance indicators (KPIs) and (2) the pathology workforce and specific
- tasks performed by (3) pathologists and (4) AP lab technicians, as well as (5) specific AI applications
- and their likelihood of routine use by 2030, (6) AI's role in integrated diagnostics, (7) pathology tasks
- 82 likely to be fully automated using AI, and (8) regulatory/legal and (9) ethical aspects of AI integration in
- pathology.
- **Interpretation**: This is the first systematic consensus study detailing the expected short/mid-term
- impact of AI on pathology practice. These findings provide timely and relevant information regarding
- future care delivery in pathology and raise key practical, ethical, and legal challenges that must be
- addressed prior to AI's successful clinical implementation.
-

Funding:

 This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

-
-
-

INTRODUCTION

 By virtue of its ability to "learn" from large volumes of electronic health record and image data without explicit programming, machine learning and artificial intelligence (AI) are set to fuel an unprecedented transformation in healthcare. In hospitals and clinics of the future, AI will become a cornerstone in the way care is delivered, contributing to more accurate diagnoses, increasingly agile, cost-effective, and 101 standardized clinical workflows, and highly effective and personalized treatments.^{1,2} Excitement and expectations regarding the potential of AI to revolutionize healthcare have continued to build, as evidenced by the growing list of medical AI publications in the form of original research articles, review papers, health policy reports, white papers and consensus recommendations from professional 105 societies, and coverage in the popular media. $1-16$ A recent survey of English-language articles indexed in PubMed showed a significant increase in the volume of medical AI research publications, from just 107 203 articles in 2005 to 12,563 in 2019.³

 Pathology has attracted growing attention as an image-rich specialty likely to be strongly impacted by recent advances in AI. The development of machine learning-based tools for automated image analysis has led to a surge in AI applications promising to revolutionize current pathology workflows, as well as 112 the advent of a new field, computational pathology.⁷ Between the years 2010-2020, approximately 23% (3,398) of all medical AI research publications were in pathology, making it the number one most-114 published specialty among the 17 specialties surveyed. A recent survey of the patent landscape from the years 1974–2021 yielded 523 patents relevant to the application of AI to digital pathology, with the 116 primary application areas being whole-slide image (WSI) acquisition, segmentation, classification, and 117 object detection.¹⁷ AI has been applied to several popular tasks in anatomic pathology (AP), including diagnosis, prognostication, and biomarker quantification, with key examples being automated 119 assessment of prognostic biomarkers such as Ki-67 in breast cancer, $18-20$ automated tumor grading in 120 prostate cancer, 2^{1-25} and diagnosis of metastatic breast cancer in lymph nodes. $26-29$ Other recently- explored AI applications in pathology have included tools for optimizing clinical laboratory workflows, 122 such as automated quality control $(QC)^{30-32}$

 Much of the growth in computational pathology has been facilitated by the increased adoption of digital pathology, providing large amounts of WSI data as a prerequisite for practical AI model development 126 and validation.³³ Concurrently, use of digital workflows within pathology has provided practices with new platforms for testing and integrating computational pathology tools within AP workflows, generating greater interest in AI from pathologists and pathology trainees. A 2018 voluntary survey of 487 international pathologists and pathology trainees revealed a generally positive attitude towards AI, with

 nearly 75% expressing interest/excitement regarding the integration of AI tools into diagnostic 131 pathology.³⁴ Furthermore, 80% of respondents predicted the integration of AI-based assistance into AP 132 workflows within the next 5–10 years.³⁴ Numerous reviews have been published on the emerging and future applications of pathology AI to cancer diagnosis, prognostication, and treatment response prediction, metastasis detection in lymph nodes, single and multiplex biomarker quantification, tumor content/cellularity assessment for molecular testing, mutation status prediction, and a multitude of other 136 tasks in pathology. $35-45$

 Despite the recent progress and enthusiasm surrounding the application of AI to pathology, few 139 algorithms are currently in routine clinical use,^{37,46} with a dearth of prospective multi-center, randomized 140 trials present evaluating the impact of these algorithms in clinical settings.^{47,48} Further, ethical concerns have been raised regarding potential patient data privacy breaches, biased datasets producing systemic algorithmic bias, potential harm related to erroneous or misleading AI-generated outputs, and 143 exacerbation of healthcare disparities due to unequal access to Al.⁴⁹ All of these factors, along with hurdles related to regulatory approval and reimbursement for AI products, have contributed to a 145 significant AI "translation gap" in pathology. While much has been written regarding the various opportunities and challenges surrounding AI in pathology, to date no systematic survey of opinions exists regarding the direct role of AI in pathology from the short to medium term perspective (the next decade) from those with dedicated expertise in digital and computational pathology. To address this knowledge gap, we conducted a consensus survey to gain detailed insight into the current challenges, expectations, and perspectives surrounding the role of AI in pathology, as seen from the point of view of an international panel of clinically active "early adopters" with hands-on experience developing and evaluating the clinical performance and utility of AI algorithms. For the survey, we chose to apply the Delphi method, a robust and widely accepted tool in medicine for building consensus among experts 154 that has been shown to outperform standard statistical methods.^{50,51}

 A Delphi study involves a panel of experts who rate a series of statements, usually in a binary (e.g., agree/disagree) or semi-quantitative (e.g., Likert scale) manner. These statements might be produced after a systematic literature search or by surveying the same experts through a preliminary survey with open-ended questions (typically referred to as "Round 1"). Rating of statements is done over multiple consecutive rounds, during which the statements reaching the consensus criterion are omitted from subsequent rounds. Raters are then invited to reconsider their responses based on the group's mean or median ratings from previous rounds. Studies are typically terminated when consensus has been 163 reached, responses are stable, or after a pre-fixed number of rounds (usually two)⁵² to prevent expert fatigue. In contrast to typical single-round surveys, the Delphi technique relies on both the

- anonymization of responses to avoid bias and the use of experts and structured communication
- 166 through an iterative pathway to reach more reliable conclusions.⁵³
-

 The goals of our study were to: 1) investigate the expected impact of AI on pathology; 2) forecast the extent of clinical AI implementation in the specialty by the end of this decade; and 3) provide specific insights into which technical, legal, regulatory, and ethical aspects of AI integration will require the most attention from pathology laboratories in the coming years. We expect the results of this study to be of broad interest to practicing pathologists, pathology trainees, pathology assistants and laboratory technicians, patients, physicians from other medical specialties, professional societies, hospital administrators, regulatory bodies, and researchers in academia, industry, and government.

MATERIALS AND METHODS

Expert Panel Recruitment

Candidates for the expert panel were selected by the research team using the following eligibility

criteria: 1) professionals working within the specialty of pathology (anatomic and/or laboratory

medicine) with an MD (or equivalent medical degree, such as an MBBS) and/or PhD, and 2) authorship

of at least one peer-reviewed publication in the area of CPath/AI within the four years preceding the

- study (2016–2020) indexed in PubMed.
-

 Invitations to participate in the study were sent in December 2020 to 39 candidates meeting the selection criteria. A total of 24 experts (60%) accepted and completed all three rounds of the survey. Detailed characteristics of the panelists are summarized in **table 1**. The majority of experts were practicing in North America (54%), with the remainder practicing in Europe, Japan, and New Zealand. The panelists were distributed across 10 different pathology subspecialties, with a third of panelists explicitly specializing in informatics, computational pathology, and/or digital pathology. Finally, the range of years in professional practice was mostly spread evenly across the panelists, with the majority having been in practice for 11–20 years (33%).

Table 1. Characteristics of the panelists

194

195

196 *Delphi Study Development*

197 To obtain a reliable consensus of opinions, the Delphi study was conducted over three rounds via a 198 series of detailed questionnaires combined with controlled opinion feedback.⁵⁴ The flowchart for the

199 study is summarized in **figure 1**.

200

which will be destroyed) by 2030?

3 What new tasks will pathologists be involved in?

203

 In Round 1, a preliminary review of the pathology AI literature, along with the research team's empirical experience, was used to generate an open-ended questionnaire containing a set of 12 questions geared toward eliciting the ideas and opinions of the expert panelists regarding the following three topics: 1) forecasting the future of AI in pathology, 2) specific AI applications in pathology, and 3) ethical and regulatory aspects (**table 2**). The panelists' responses to these open-ended questions were combined and distilled (all original answers were analyzed, and similar answers within the same category were grouped and summarized into a single statement, with the original wording used by the panelists reproduced wherever possible) into a series of questionnaire statements used in the subsequent survey rounds. 213 **Table 2**. Round 1 questions **Section 1: Forecasts about the future** (please answer according to what you believe will happen by 2030, instead of what you would like to see happen) On what key performance indicators related to pathology do you believe AI will have a positive impact? 2 How do you think AI will impact the pathology workforce (jobs which will be created and jobs

- 215 216
- 217 In Round 2, the panelists were asked to rate each of the questionnaire statements on a 7-point Likert
- 218 scale (from 1 to 7), with different scores designed to fit different categories of questions. For example, a
- 219 score of 1 might indicate "Very strongly disagree", "Impossible" (with regard to likelihood of an event
- 220 occurring), "Disappear"(with regard to job number or availability), or "Not involved at all" (with regard to
- 221 degree of involvement in specific tasks), whereas a score of 7 might indicate "Very strongly agree",
- 222 Certain", "Dramatically increase", or "Daily involvement", depending on the question, with higher scores
- 223 generally representing a more favorable opinion toward the future role or impact of AI on Pathology
- 224 (**table 3**).
- 225

226 **Table 3.** Likert scales for the different sections (7-point)

 In Round 3, the panelists were asked to re-rate all statements which did not reach consensus during Round 2. Consensus on statements was defined, a priori, as having an interquartile range (IQR) of less 231 than 1 (IQR ≤ 1) for ratings along the 7-point Likert scale.^{55,56} During Round 3, the panelists were shown their Round 2 ratings on each statement, along with the median and IQR for the group as a whole, and finally given the option to change their previous ratings, if desired.

 All questionnaires were completed via an online Google Form (Google Inc, Mountain View, CA, USA), with individualized links to the form e-mailed to each panelist. The survey participants remained anonymous to one another during all three Rounds, with each participant able to view only their own responses to each statement during Rounds 1 and 2, along with the anonymized group medians and IQRs during Round 3.

Statistical Analysis

To examine whether any significant differences in panelist scores were present based on gender,

practice location, pathology subspecialty, or years in practice, Wilcoxon rank-sum tests (two-tailed,

alpha = 0.05 significance criterion) were performed. All analyses were performed using Microsoft Excel

 (Microsoft Corporation, Redmond, WA, USA) and STATA v16 (StataCorp LLC, College Station, TX, USA).

RESULTS

Survey Rounds

 The unstructured first Delphi round allowed the panelists relative freedom in expressing their individual thoughts on topics they felt were important or relevant to the future of AI in pathology over the next decade. This resulted in the generation of 180 summative statements spanning the following nine categories: 1) impact of AI on key performance indicators (KPIs), 2) impact of AI on the pathology

 workforce, 3) impact of AI on pathologist tasks, 4) impact of AI on pathology technician tasks, 5) specific applications of AI in pathology, 6) role of pathology AI in integrated diagnostics, 7) pathology tasks likely to be fully automated by AI, 8) regulatory and legal aspects of AI integration, and 9) ethical aspects of AI integration.

 One of the motivations behind using the Delphi method was its ability to achieve greater consensus (a reduction in variance across rounds, as measured by the IQR) among a limited number of expert 261 panelists. After Round 2, responses to 48 of the 180 (26.7%) statements reached consensus (IQR \leq 1). After Round 3, the panelists had reached consensus on 141 of the 180 (78.3%) statements. The mean and median Likert scores across the panelists for each of the 180 statements ranged from 3.04 to 6.83 (mean), and from 3 to 7 (median), respectively. Tables 4 through 10 present the 100 statements 265 (spread across seven general categories) that achieved high directional consensus (defined as IQR ≤ 266 1, *and* both mean and median scores of either ≤ 3 or ≥ 5) among the expert panelists. For these 100 statements, two-tailed Wilcoxon rank sum tests demonstrated no significant differences in Likert scores between the various panelist comparison groups (female vs. male, North American vs. non-North American, subspecialty informatics or computational/digital pathology vs. other subspecialty, and < 10 years vs. ≥ 11 years in practice) on 85 of the 100 statements. The remaining 15 statements are further discussed in the corresponding sections below, which summarize the most significant results of the survey according to topic/category

Impact of AI on Pathology Key Performance Indicators (KPIs)

 In general, there was agreement that AI would help improve laboratory KPIs, such as turnaround time, diagnostic accuracy, the detection rate for rare events (for example, small foci of primary or metastatic tumor), and quality of diagnostic reports (**table 4**). However, it was also anticipated that histopathologic analyses would become more quantitative, and that diagnostic reports would become more complex. There was also agreement that AI would lead to greater standardization of diagnostic and pre-analytical processes, such as tissue sectioning, staining techniques, and workflows. As a result of these anticipated improvements in KPIs, it was expected that there would be an increase in the satisfaction of referring physicians. A statement regarding the likelihood of the cost per case decreasing with the use of AI failed to reach consensus, although a majority of the experts predicted the cost per case would not decrease with medium term AI use (within the next 8-10 years). In addition, the panelists did not reach consensus on whether the number of second-opinion consultations would decrease as a result of AI adoption.

287

288 **Table 4**. Statements on which high directional consensus was reached regarding the impact of AI on

289 pathology key performance indicators (KPIs)

By 2030, due to the integration of AI in the pathology setting			
Key performance indicator	Mean	Median	Result
Standardization of pre-analytical processes (staining and slicing techniques) will increase	5.38	5	Agree
Diagnostic accuracy will increase	5.67	6	Strongly agree
Diagnosis and grading of tumors will be more standardized, bringing more objectivity to the diagnosis of certain entities that are currently subject to high interobserver variability	6.04	6	Strongly agree
Detection of rare events (small metastases, small tumor foci) will increase	5.88	6	Strongly agree
Analyses will be more quantitative	6.21	6	Strongly agree
Completeness of reports will increase	5.13	5	Agree
Complexity of reports will increase	5.13	5	Agree
Quality of reports will increase	5.38	5	Agree

- 290 AI, artificial intelligence.
- 291 292

 Table 4 presents those statements regarding the impact of AI on pathology KPIs for which there was high directional consensus among the panelists. Overall, these results projected, by the year 2030, growth in computational pathology as a subspecialty with AI applications assisting pathologists in making diagnoses that are more accurate, standardized, objective, quantitative, and complete.

297

298 *Impact of AI on the Pathology Workforce and Specific Tasks*

 There was agreement that the number of jobs for pathologists, as well as administrative staff, would likely remain the same. However, a modest increase in the number of jobs for technicians and information technology (IT) professionals was expected. While the size of the overall pathology job market was not expected to vary greatly due to the adoption of AI, the types and frequencies of tasks performed by pathologists and pathology laboratory technicians were expected to change significantly. There was agreement that AI would facilitate subspecialization in pathology, with the number of pathologists specializing in computational pathology greatly increasing. Tables 5 and 6 present the expected impact of AI on the pathologist (**table 5**) and pathology laboratory technician (**table 6**) workforces and associated tasks.

- 308
- 309
- 310

311 T**able 5**. Statements on which high directional consensus was reached regarding the impact of AI on pathologist workforce and tasks

313 AI, artificial intelligence; IT, information technology; EHR, electronic health record; QA/QC, quality 314 assurance/quality control.

315

316

317 **Table 6.** Statements on which high directional consensus was reached regarding the impact of AI on 318 pathology lab technician workforce and tasks

 AI, artificial intelligence; SOP, standard operating procedure; QA/QC, quality assurance/quality control.

 There was agreement that, by 2030, pathologists would be routinely involved in new tasks related to the incorporation of AI into their workflows, such as interpreting diagnostic outputs from AI algorithms, evaluating AI software, and performing validation and quality assurance/quality control (QA/QC) for AI solutions and AI-rendered diagnoses. There was also agreement pathologists would be directly participating in the design and development of AI solutions and, based on the availability of new data 327 generated by AI, they would also be contributing to the definition of new categories of patients. As a result of AI adoption, pathologists were also expected to be more involved in ancillary activities, such as research and participation in multidisciplinary conferences and tumor boards. The panelists also agreed pathologists would sometimes be more involved in meeting directly with patients, including more frequent inclusion in patient treatment decision-making.

 Compared to the panelists who had been in practice for 11 years or longer, those in practice for 10 or fewer years (7 panelists) more strongly agreed that digital pathologic diagnosis without the use of physical glass slides would be routine by 2030 (*p* = 0.041), with a median score of 7 (compared with a median score of 6, for those with 11 or more years of practice) and mean score of 6.43 (compared to a mean score of 5.23, for those with 11 or more years of practice). The same group also more strongly agreed that interpretation of computationally derived measurements and evaluations would be routine (*p* = 0.048), with a median score of 7 (compared with a median score of 6, for those with 11 or more years of practice) and mean score of 6.71 (compared to a mean score of 5.82, for those with 11 or more years of practice).

 The work of pathology technicians was also expected to undergo major changes as a result of AI adoption (**table 6**). Technicians would be routinely involved in tasks related to new digital and computational workflows, such as scanner operation, device calibration, and QA/QC of digitized images. There was no consensus, however, as to whether technicians would be directly participating in AI-assisted diagnosis, although a slight majority of the panelists surveyed thought this would be the case.

The panelists subspecializing in informatics or computational/digital pathology (8 panelists) more

strongly felt that pathology laboratory technicians would routinely be providing digital pathology support

for pathologists and other users (for example, by performing device calibration and other tasks) (*p* =

0.005), with a median score of 7 and a mean score of 6.63 (as compared to a median of 6 and a mean

 of 5.50 for those not subspecializing in informatics or computational/digital pathology). Similarly, this group also felt more strongly that pathology laboratory technicians would be routinely involved in assessing and improving the consistency of histologic tissue preparation and staining to make images more suitable for AI (*p* = 0.049), with a mean score of 6.25 (as compared to a mean of 5.63, with the same median of 6, for those not subspecializing in informatics or computational/digital pathology).

359

360 *Applications of AI to Pathology and Integrated Diagnostics*

 AI was expected to positively impact many aspects of the pathology workflow. The panelists proposed several specific applications they thought would likely be in routine use in pathology laboratories by the year 2030 (**table 7**). Regarding the analysis and interpretation of histologic images, routine applications included algorithms for the identification of hotspot areas (for example, during mitotic counts), detection of microorganisms (such as acid-fast bacilli and *Helicobacter pylori*) and cancer, and assistance with tumor grading. The panelists were also certain AI would be in routine use for the automated quantification of immunohistochemical (IHC) and immunofluorescent (IF) biomarker stains, such as Ki-67, estrogen receptor (ER), progesterone receptor (PgR), and programmed cell death ligand 1 (PD-L1),

369 as well as the counting of mitotic figures and lymphocytes on hematoxylin and eosin (H&E) stained

- 370 tissue, and the identification of lymph node metastases and, in particular, micrometastases.
- 371

372 **Table 7**. Statements on which high directional consensus was reached regarding AI applications in 373 pathology

374 AI, artificial intelligence; IHC, immunohistochemistry; IF, immunofluorescence; ER, estrogen receptor; 375 PgR, progesterone receptor; PD-L1, programmed cell death ligand 1; H&E, hematoxylin and eosin; PgR, progesterone receptor; PD-L1, programmed cell death ligand 1; H&E, hematoxylin and eosin; 376 QA/QC, quality assurance/quality control; AFB, acid-fast *Bacillus; H. pylori, Helicobacter pylori;* STAT6, 377 signal transducer and activator of transcription 6.

378

379

380 Tasks which are currently performed manually, but which were expected to be replaced by AI

381 automation by the year 2030, included the provision of size measurements (e.g., tumors) and the

 detection of perineural and lymphovascular invasion in malignancies. In addition, it was expected that AI-based computational/virtual staining would replace the need for multiplex histochemistry and IHC/IF.

 Within a decade, AI was expected to increase diagnostic efficiency by prioritizing regions of interest suspicious for cancer involvement for pathologists to review first, pre-populating relevant diagnostic report fields using data extracted from the medical record and/or gross description, and pre-populating diagnostic reports based on AI interpretation of whole-slide images. In addition, AI was expected to assist pathologists with making more accurate diagnoses by importing contextually relevant clinical history and other data related to a case for quick review by the pathologist during case sign-out, providing a set of differential diagnoses, and prompting second reads on cases where there was a discrepancy between the pathologist diagnosis and the diagnosis rendered by the AI algorithm.

 The panel also foresaw a significant impact of AI on other aspects of the laboratory workflow. Routine AI-assisted prioritization of cases for pathologist review, suggestions for ancillary stains to be performed, and automated ordering of additional stains were thought to be very likely by 2030 (**table 7**). In terms of differences in opinion between the various panelist subgroups, those subspecializing in informatics or computational/digital pathology less strongly believed that AI would routinely be used for the quantification of eosinophils in eosinophilic esophagitis (*p* = 0.049), with a mean score of 5.75, as compared to a mean of 6.31 (with the same median of 6), for the other subspecialists.

 AI was expected to foster the integration of pathology with other diagnostic modalities, such as radiology and genomics, by: 1) identifying histologic regions of interest to be sampled for genomic testing; 2) correlating morphologic and genomic information to help interpret genetic aberration; 3) comparing tumor extent on histology slides and radiologic images; and 4) interpreting tumor treatment response in radiologic images, based on pathology data. Multimodal-AI was also expected to enable the combination of diverse types of diagnostic data (gross/macroscopic, microscopic, radiologic, and genomic) in a single interface, and to facilitate the use of integrated diagnostic reports for certain diseases, such as prostate cancer (**table 8**). Consequently, it was felt AI-powered integrated diagnostics would likely lead to significant advances in the personalization of healthcare by creating new categories of patients based on differential risk stratification (prognostic) roadmaps and prediction of clinical outcomes.

 Table 8. Statements on which high directional consensus was reached regarding the role of AI in integrated diagnostics

- 416 AI, artificial intelligence.
- 417 418
- 419 The panelists with greater practice experience $(≥ 11 \text{ years})$ more strongly believed the integration of 420 pathology and radiology data would routinely be used to select patients for active surveillance versus 421 radiotherapy/surgery in prostate cancer (*p* = 0.044; equal medians of 5 but mean of 5.29 versus 4.29 422 for those with ≥11 years and ≤ 10 years of practice experience, respectively). The panelists with more 423 practice experience more strongly believed that AI would routinely be used to build risk stratification 424 (prognostic) roadmaps for patients based on histologic, radiologic, and genomic input data (*p* = 0.020; 425 equal medians of 5, means of 5.41 versus 4.43 for those with ≥ 11 years and ≤ 10 years of practice 426 experience, respectively).
	- 427
	- 428 The panelists felt it was likely that, by 2030, AI would not simply assist with, but would fully replace,
	- 429 pathologists on several manually-performed tasks. Among these were stain selection; measurement
	- 430 tasks; prioritization and triage of cases; screening for microorganisms; colorectal polyp, cervical
	- 431 cytology, and lymph node screening; and grading of breast and colorectal cancers (**table 9**). Assigning
	- 432 work to pathologists, trainees, and technicians, as well as triaging cases to the appropriate pathologist,
	- 433 were also deemed likely to be fully automated by AI.
- 434

435 **Table 9**. Statements on which high directional consensus was reached regarding pathology tasks 436 expected to be fully automated by 2030

 AI, artificial intelligence; IHC, immunohistochemistry; EHR, electronic health record; QC, quality control; AFB, acid-fast *Bacillus; H. pylori, Helicobacter pylori;* IF, immunofluorescence; ER, estrogen receptor; PgR, progesterone receptor; PD-L1, programmed cell death ligand 1; H&E, hematoxylin and eosin. 440

441

442 The panelists practicing outside of North America (11 panelists) thought it more likely that colorectal

443 polyp screening would be fully delegated to AI by the year 2030 ($p = 0.047$; mean $= 6$ and median $= 6$

444 for non-North American panelists, versus mean = 5.23 and median = 5 for North American panelists).

445 Those with more practice experience (≥ 11 years) thought it more likely that mitotic counts on H&E-

446 stained images would be fully delegated to AI (*p* = 0.036; equal medians of 6 but mean of 6.29 versus

447 5.57 for those with ≥ 11 years and ≤ 10 years of practice experience, respectively).

448

449 *Regulatory and Ethical Aspects of AI Integration in Pathology*

450 The panelists foresaw significant regulatory and ethical challenges posed by the integration of AI in

451 pathology (**table 10**). While some panelists initially suggested such issues might not pose a challenge

452 to the application of AI in pathology, since the pathologist (or another physician) always takes the

453 ultimate responsibility for the diagnostic, therapeutic or prognostic use of AI, the final consensus

454 opinion overruled that initial suggestion. In principle, the panel agreed that both primary diagnostic and

455 secondary (e.g., advisory/assistive) algorithms would have to meet strict regulatory requirements.

456 There was agreement that regulatory bodies would create new guidelines addressing the integration of

- 457 AI into pathology, which would provide specific validation procedures and simplify regulatory pathways
- 458 for AI tools, although regulatory clearance of AI software would still be a lengthy and costly process.
- 459
- 460 **Table 10**. Statements on which high directional consensus was reached regarding regulatory and 461 ethical aspects
	- **By 2030, regarding the integration of AI in pathology…** *Aspect Mean Median Likelihood* A set of new guidelines will be developed, specifically addressing the integration of AI in pathology 6.63 7 Very strongly agree Specific validation procedures for different types of AI tools will be defined by regulatory bodies 6.46 7 Very strongly agree The introduction of AI-based diagnostic modalities will require regulatory supervision, both related to the quality of the rendered diagnosis and the ultimate destination of the diagnostic information 6.83 7 Very strongly agree As long as AI is used as a supportive method, ethical issues will be minor. However, when AI takes over tasks from the pathologist, i.e., making a diagnosis without human oversight, it will face major ethical challenges. 6.58 7 Very strongly agree Pathologists will still be legally responsible for diagnoses made with the help of AI 6.25 7 Very strongly agree Meeting regulatory requirements for most AI applications will be a lengthy and costly process, as it will involve large-scale prospective studies 5.46 5.5 Strongly agree Definition of end-points for validation clinical studies will be a common problem 5.50 6 Strongly agree Post-marketing surveillance will pose important challenges, due to algorithm drift 5.50 6 Strongly agree Regulatory approval of AI tools used for definitive (primary) diagnosis will be very strict, but AI used for advisory purposes (secondary) will also have to meet strict regulatory conditions 6.04 6 Strongly agree CLIA regulations and clarification surrounding the use of laboratory data within pathology and laboratory processes versus outside of the laboratory will be reviewed and updated 5.63 6 Strongly agree Governments will actively promote innovation in the areas of AI and medicine, fostering the advancement of AI in pathology 5.88 6 Strongly agree Legal disputes will often arise regarding who should assume liability (pathologist, institution, developer, commercial vendor…) for diagnostic errors induced by AI 5.67 6 Strongly agree AI and technology will be included in the educational curricula for medical students, pathologists, and analysts to help them deal with this rapidly evolving method of support and its ethical implications 5.88 6 Strongly agree Hurried pathologists will often take "shortcuts" by accepting AI interpretations without verification 5.08 | 5 | Agree

- AI, artificial intelligence; CLIA, Clinical Laboratory Improvement Amendments.
-

 There was also agreement that the regulatory approval of adaptive algorithms, which continuously evolve in response to new input data, would be possible, but that algorithm drift would pose important challenges that would need to be tackled by close post-market surveillance. It was also anticipated that legal disputes would arise regarding who should assume liability for diagnostic errors induced by AI, with pathologists still being held legally responsible for AI-assisted diagnosis.

With regard to differences in opinion between the various panelist subgroups, the North American

panelists more strongly believed that CLIA regulations and clarification surrounding the use of

laboratory data within pathology, as well as laboratory processes, would need to be reviewed and

473 updated ($p = 0.031$; median = 6 vs. median = 5 and mean = 6 vs. mean = 5.18 for North American vs.

 other panelists, respectively). Those subspecialized in informatics or computational/digital pathology less strongly believed that legal disputes would often arise regarding who should assume liability for

- 476 diagnostic errors induced by AI ($p = 0.018$; mean $= 4.88$ and median $= 5$), compared to those not
- subspecialized in those areas (mean = 6.06 and median = 6).
-

 Overall, the panel acknowledged there would be major ethical issues arising from the full delegation of tasks to AI algorithms, believing it likely that hurried pathologists would often accept AI interpretations without sufficient verification. On the other hand, there was disagreement between the panelists regarding whether the black box nature of AI algorithms would cause pathologists to often make diagnoses without enough clinical explainability. The panelists who had been in practice fewer years (≤ 10 years) more strongly believed that ethical issues would result from data inferences which might 485 compromise patient anonymity ($p = 0.004$; mean = 6 and median = 6), compared to those in practice ≥ 486 11 years (mean = 4.82 and median = 5).

 Finally, there was general consensus that ethical issues were expected to arise due to: 1) risk for diagnostic error resulting from the use of potentially biased algorithms trained on datasets lacking sufficient demographic diversity; and 2) the lack of proper informed consent when using patient data (which the panel agreed would become a common practice). Nevertheless, the panelists expected official regulatory bodies would do their part to overcome the aforementioned ethical and legal challenges, and funding bodies would actively promote innovation in AI and medicine, thereby fostering

 the advancement of AI in pathology. It was also anticipated AI would be integrated into both medical school and continuing medical education curricula for pathologists in current practice, in order to help them adapt to this rapidly evolving area and its associated legal and ethical implications.

DISCUSSION

 From this first ever consensus study of a panel of 24 international experts with first-hand experience working in the field of computational pathology and AI (almost all of whom are also pathologists in active clinical practice), we obtained specific insight into consistently agreed-upon opportunities and challenges, as well as perspectives and predictions, relevant to the expected role of AI in pathology over the next decade. Our panel was composed of experts of both genders, practicing in 11 different countries, specializing in a wide range of pathology subspecialties, and with a wide range of years in practice (with all panelists having attending pathologist/faculty status). Despite this diversity in the expert panel, the panelists were able to reach consensus agreement on 140 (78.3%) of the 180 items surveyed.

 There was particularly strong consensus AI would improve the KPI of diagnostic accuracy, at least partially by assisting with the detection of rare events (such as small tumor foci and metastases), standardizing the diagnosis and grading of tumors, and making histopathologic analyses more quantitative. There was also particularly strong consensus that the number of specialized computational pathologists would greatly increase, and that pathologists would be more involved in diagnostic tumor boards and multidisciplinary conferences as a result of AI integration. Significant changes in the types of tasks routinely performed by a pathology laboratory technician were also expected.It was projected that laboratory technicians would be operating digital slide scanners and performing digital image management and QA/QC daily.

 It was felt to be *almost certain* that specific pathology AI applications would be in routine use by 2030 – namely, algorithms for the identification of lymph node macro- and micro- metastases, IHC/IF stain quantification (including Ki-67, ER, PgR, and PD-L1), mitosis quantification, and lymphocyte quantification. It was also felt to be *very likely* that algorithms would be in routine use for: 1) specific pre-analytical tasks, such as automated QA/QC of histologic preparation, WSI quality, and IHC controls, automated suggestion or ordering of ancillary stains and molecular tests, and automated case prioritization; 2) specific analytical tasks, such as pre-selection of cancer regions of interest and hotspot areas, microorganism detection, tumor grading, eosinophil and feature quantification, tumor area

 measurement, identification of lymphovascular and perineural invasion, diagnostic report standardization, and ensuring that all diagnostically-relevant areas in a WSI are viewed prior to report finalization; and (3) specific post-analytical tasks, such as enforcement of mandatory second reads when there is a significant discrepancy between the pathologist-rendered and AI-rendered diagnoses. The panelists felt it *very likely* that many of the preceding tasks, along with colorectal polyp and cervical cytology screening, case triage and assignment to pathologists, and contextual electronic health/medical records data lookup, would no longer be performed by pathologists in the year 2030, as they will have been *fully delegated* to AI. These predictions are consistent with the relatively high 535 representation of many available applications in the existing pathology AI research literature. ^{29,31,41,43,57–} 536 63

 At the same time, it is interesting to note that many of the applications projected to be in routine use within the next decade address basic or mundane tasks already being performed by pathologists, rather than advanced or "aspirational" tasks pathologists do not currently perform (such as prediction of molecular biomarker status or clinical outcomes directly from morphologic features on H&E-stained 542 slides). The relative projected likelihoods of these two dominant categories of AI applications ("basic" versus "aspirational") being in routine use by 2030 seems, in many ways, contrary to the relative degree of attention paid to these categories by the research community and industry stakeholders. $35,41,64-66$ For example, in a recent survey from 2021, 67 75 computational pathology domain experts from academia and industry (48% with medical and 52% with non-medical backgrounds) were asked to provide their subjective rankings regarding the degree of interest, importance, and/or promise of 12 solid tumor-specific pathology AI applications. Among the applications surveyed, those falling within the advanced/aspirational categories were consistently rated the most highly, while those falling within the more basic/mundane categories (such as QA/QC, tumor grading, and subtyping) were rated the lowest, with the most highly-rated application being prediction of treatment response directly from H&E images, followed by prediction of genetic mutations, gene expression, and survival directly from H&E images, respectively. Although "degree of interest/importance/promise" is not exactly equivalent to the "likelihood of routine near-term adoption", the somewhat discrepant findings between the two surveys, each of which targeted different participant populations, suggests that those with non-medical and/or industry backgrounds (who collectively formed the majority of participants in the cited study) might be more optimistic about the near-term role and importance of advanced/"aspirational" AI applications in pathology than pathologists with first-hand experience working in the areas of computational pathology/AI, who tend to have a more practical perspective regarding those AI applications likely to enjoy widespread adoption in the near to medium term. It was unclear from our study why more advanced/"aspirational" AI tools were not predicted to be in routine use within the next decade.

 Perhaps, it was felt that such tools, though interesting from a research standpoint, would never reach the level of performance required for clinical adoption. Or, in order to have a sufficient level of performance for these tools, the fundamental AI infrastructure addressing the "basic" tasks would have to be completed first, paving the way for full diagnostic AI algorithm clinical validation and regulatory clearance. It remains for future studies to explore the reasons underpinning the results observed in this (and other) surveys regarding clinical AI.

 Only a few other studies have sought to survey the opinions of various stakeholders regarding AI in pathology. In a 2018 survey of 363 practicing pathologists and 124 pathology trainees from 54 countries (46% female, 56% practicing in the United States, Canada, or the United Kingdom, and 43% in practice for ≤10 years) on general perspectives regarding the integration of AI into diagnostic pathology, 81% of respondents predicted that AI would be integrated into pathology workflows within 574 the next 5–10 years.³⁴ In the same survey, 38% of respondents felt that AI would have no impact on pathologist employability, 42% felt that it would create new positions and improve employment prospects, and 20% were either concerned or extremely concerned that AI would displace them from their jobs. Approximately 72% of the respondents also felt that AI tools could increase or dramatically increase diagnostic efficiency, with the remaining 28% being unsure of AI's impact on efficiency, or of the opinion that AI would have either no impact or a negative impact on efficiency. In contrast to the more heterogeneous respondent demographic in that survey, the participants in our survey were composed almost exclusively of practicing pathologists with experience in computational pathology/AI. Although the consensus perspectives from our survey were more optimistic regarding the impact of AI on the pathologist workforce, there was similar reservation regarding whether AI integration would truly lead to increased efficiency, in terms of cost per case (one of the KPI's which failed to reach consensus in our study) and turnaround time per case (which failed to reach high directional consensus).

 Finally, it is worth noting some of the areas where there was either a lack of consensus among the panelists, or consensus toward a less optimistic perspective on the topic in question. There was a lack of consensus regarding whether AI would reduce the cost per case or the number of cases requiring pathologist review (after automated AI-based filtering of negative/normal cases), and whether it would increase patient satisfaction. There was also a lack of consensus regarding many regulatory aspects related to AI integration. For example, the panelists were uncertain whether it would become possible in the near future for approved developers to circumvent the requirement for individual approval of each new application, or whether legal and administrative barriers would be overcome regarding the use of de-identified images for research and education. There was general agreement that regulatory issues would still pose a challenge to the use of AI, even when the pathologist or another physician was the

 final decision-maker regarding diagnosis, prognostication, or treatment. There were differences of opinion surrounding several ethical aspects of AI integration, including whether AI outputs used for clinical decision-making would always need to be manually reviewed by a pathologist, or whether other healthcare professionals would start using AI tools to diagnose cases without the aid of a pathologist. There was uncertainty around whether the "black box" nature of many AI tools would cause pathologists to make diagnoses without enough clinical explainability, and a lack of consensus regarding whether pathologists would occasionally make diagnoses contrary to their own judgment because of AI software recommendations. There was also no consensus on whether AI would lead to 605 de-skilling of pathologists (a subject which remains controversial within the pathology community³⁴), or whether it would be possible to ensure that pathologists took full responsibility for double-checking and confirming AI-rendered diagnoses. Due to the current AI "translation gap" in pathology, there have been either no, or only a limited number of, studies evaluating the impact of AI tools on pathologist 609 behavior,^{25,26,59,68–71} laboratory cost expenditures, medicolegal liability, or patient satisfaction. Therefore, the current lack of consensus among the panelists regarding the preceding topics is understandable and expected to be resolved as (1) more AI tools reach maturity and come to be evaluated in prospective clinical settings, and (2) more consideration is directed toward ensuring that AI models are integrated into pathology workflows in a manner that maximizes accuracy, time and cost efficiency, 614 safety, transparency, accountability, and positive impact on patient outcomes. 8,9,15,49,72

 Our study was subject to several limitations. Given the voluntary nature of participation and the substantial time commitment required to complete all three Delphi rounds, not all experts who were initially invited agreed to participate in the study, introducing the possibility of non-response bias. In addition, the proportion of female participants (16.7%) was much lower than the proportion of male participants. Although out of the 39 candidates originally invited to participate in this study 15 (38·9%) were women, possibly reflecting a relative underrepresentation of women in the pathology informatics and more specifically, the computational pathology/AI space, finally only four completed our survey. Only one of the participants was a cytopathologist (who also subspecialized in other areas of anatomic pathology), which may reflect the current underrepresentation of this subspecialty in computational pathology/AI due to the challenges of generating and storing z-stacked WSIs (which may resolve with 626 the introduction of dedicated cytology whole-slide scanners in the near future). 42 Also, as most of the participants were practicing in North America and Europe, the results of this study may reflect a predominantly North American/European perspective that differs from the perspectives of those practicing in other parts of the world. Lastly, as our study was targeted toward a specific respondent demographic, individuals from other stakeholder groups (such as pathology trainees, pathologists with little or no experience in computational pathology/AI, pathology laboratory technicians, computer

 scientists and others working in the computational pathology/AI space with non-medical backgrounds, physicians in other specialties, and patients) were not represented in our results. We anticipate all

- above issues to be sufficiently addressed in forthcoming studies, and that our survey, with its freely-
- available data collection forms, may serve as a model study for independent validation and extension.
-

 We hope the results of this first systematic consensus study have provided a detailed vision of what pathology might look like in the year 2030, from the point of view of those with first-hand experience developing and evaluating clinical AI tools. Furthermore, we feel this study lays the groundwork for future follow-up studies in 3-5 years' and 10 years' time, assessing the evolution of expectations and challenges as the field of computational pathology progresses. Clearly, AI is expected to have a deep impact on the specialty of pathology, with several pathology AI applications anticipated to be in routine use by 2030, including some that will fully replace pathologists on specific tasks. The results of our study provide detailed insight into the current challenges, expectations, and perspectives surrounding 645 the near to medium term role of AI in pathology, including timely and relevant information regarding how pathology care might be delivered in the future, assuming all regulatory and ethical questions are 647 addressed. 48,73 We expect these findings will be of broad interest to a wide variety of stakeholders, including pathologists, pathology trainees and laboratory technicians, hospital administrators, researchers in academia, industry, and government, patients, professional societies, and regulatory

- bodies.
-
-

REFERENCES

 1. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.* 2019;**25(1)**:44–56. doi: 10.1038/s41591-018-0300-7, PMID 30617339.

 2. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare [internet]. *Nat Med.* 2019;**25(1)**:24–9. doi: 10.1038/s41591-018-0316-z, PMID 30617335.

 3. Meskó B, Görög M. A short guide for medical professionals in the era of artificial intelligence. *NPJ Digit Med.* 2020;**3**:126. doi: 10.1038/s41746-020-00333-z, PMID 33043150.

 4. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. *J Intern Med*. 2020;**288(1)**:62–81. doi: 10.1111/joim.13030, PMID 32128929.

 5. Berbís MA, Aneiros-Fernández J, Mendoza Olivares FJM, Nava E, Luna A. Role of artificial intelligence in multidisciplinary imaging diagnosis of gastrointestinal diseases [internet]. *World J Gastroenterol.* Jul 21, 2021;**27(27)**:4395–412. doi: 10.3748/wjg.v27.i27.4395, PMID 34366612.

 6. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. *Nat Med*. 2022;**28(1)**:31–8. doi: 10.1038/s41591-021-01614-0, PMID 35058619.

 7. Abels E, Pantanowitz L, Aeffner F, et al. Computational pathology definitions, best practices, and recommendations for regulatory guidance: a white paper from the Digital Pathology Association. *J Pathol.* 2019;**249(3)**:286–94. doi: 10.1002/path.5331, PMID 31355445. 8. Müller H, Holzinger A, Plass M, Brcic L, Stumptner C, Zatloukal K. Explainability and causability for artificial intelligence-supported medical image analysis in the context of the European in vitro diagnostic regulation. *New Biotechnol.* 2022;**70**:67–72. doi: 10.1016/j.nbt.2022.05.002, PMID 35526802. 9. McGenity C, Treanor D. Guidelines for clinical trials using artificial intelligence – SPIRIT-AI and CONSORT-AI. *J Pathol.* 2021;**253(1)**:14–6. doi: 10.1002/path.5565, PMID 33016344. 10. FDA. Artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD) action plan. p. 1–7; Jan 12, 2021 [cited Jun 7, 2022]. Available from: https://www.fda.gov/media/145022/download. 11. FDA authorizes software that can help identify prostate cancer; Sep 21, 2021. FDA news release [cited Jun 7, 2022]. Available from: https://www.fda.gov/news-events/press- announcements/fda-authorizes-software-can-help-identify-prostate-cancer. 12. Das R. Five technologies that will disrupt healthcare by 2020. Forbes [cited Jun 7, 2022]. Available from: https://www.forbes.com/sites/reenitadas/2016/03/30/top-5-technologies-disrupting- healthcare-by-2020/?sh=5b175d246826; Mar 30, 2016. 13. Khosla V. Technology will replace 80% of what doctors do. Fortune [cited Jun 7, 2022]. Available from: https://fortune.com/2012/12/04/technology-will-replace-80-of-what-doctors-do/; Dec 4, 2012. 14. Longoni C, Morewedge CK. AI can outperform doctors. So why don't patients trust it? *Harv Bus Rev*. Oct 30, 2019. 15. Jackson BR, Ye Y, Crawford JM, et al. The ethics of artificial intelligence in pathology and laboratory medicine: principles and practice. *Acad Pathol.* 2021;**8**:2374289521990784. doi: 10.1177/2374289521990784, PMID 33644301, PMCID PMC7894680. 16. Vought RT, Office of Management and Budget. Memorandum for the heads of executive departments and agencies: guidance for regulation of artificial intelligence applications. *White House memo*. Jan 2020;**7**:1–15. 17. Ailia MJ, Thakur N, Abdul-Ghafar J, Jung CK, Yim K, Chong Y. Current trend of artificial intelligence patents in digital pathology: A systematic evaluation of the patent landscape. *Cancers*. 2022;**14(10)**:2400. doi: 10.3390/cancers14102400, PMID 35626006. 18. Hida AI, Omanovic D, Pedersen L, et al. Automated assessment of Ki-67 in breast cancer: the utility of digital image analysis using virtual triple staining and whole slide imaging. *Histopathology*. 2020;**77(3)**:471–80. doi: 10.1111/his.14140, PMID 32578891. 19. Saha M, Chakraborty C, Arun I, Ahmed R, Chatterjee S. An advanced deep learning approach for Ki-67 stained hotspot detection and proliferation rate scoring for prognostic evaluation of breast cancer. *Sci Rep*. 2017;**7(1)**:3213. doi: 10.1038/s41598-017-03405-5, PMID 28607456.

 20. Yousif M, van Diest PJ, Laurinavicius A, et al. Artificial intelligence applied to breast pathology. *Virchows Arch*. 2022;**480(1)**:191–209. doi: 10.1007/s00428-021-03213-3, PMID 34791536. 21. Xu H, Park S, Hwang TH. Computerized classification of prostate cancer Gleason scores from whole slide images. *IEEE ACM Trans Comput Biol Bioinform*. 2020;**17(6)**:1871–82. doi: 10.1109/TCBB.2019.2941195, PMID 31536012. 22. Bulten W, Pinckaers H, van Boven H, et al. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. *Lancet Oncol.* 2020;**21(2)**:233–41. doi: 10.1016/S1470-2045(19)30739-9, PMID 31926805. 23. Nagpal K, Foote D, Liu Y, et al. Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer. *NPJ Digit Med*. 2019;**2**:48. doi: 10.1038/s41746-019- 0112-2, PMID 31304394. 24. Ström P, Kartasalo K, Olsson H, et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. *Lancet Oncol*. 2020;**21(2)**:222–32. doi: 10.1016/S1470-2045(19)30738-7, PMID 31926806. 25. Pantanowitz L, Quiroga-Garza GM, Bien L, et al. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study. *Lancet Digit Health*. 2020;**2(8)**:e407–16. doi: 10.1016/S2589-7500(20)30159-X, PMID 33328045. 26. Steiner DF, MacDonald R, Liu Y, et al. Impact of deep learning assistance on the histopathologic review of lymph nodes for metastatic breast cancer. *Am J Surg Pathol.* 2018;**42(12)**:1636–46. doi: 10.1097/PAS.0000000000001151, PMID 30312179. 27. Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. *JAMA.* 2017;**318(22)**:2199–210. doi: 10.1001/jama.2017.14585, PMID 29234806. 28. Campanella G, Hanna MG, Geneslaw L, et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images*. Nat Med.* 2019;**25(8)**:1301–9. doi: 10.1038/s41591-019-0508-1, PMID 31308507. 29. Yousif M, van Diest PJ, Laurinavicius A, et al. Artificial intelligence applied to breast pathology. *Virchows Arch*. 2022;**480(1)**:191–209. doi: 10.1007/s00428-021-03213-3, PMID 34791536. 30. Haymond S, McCudden C. Rise of the machines: artificial intelligence and the Clinical Laboratory. *J Appl Lab Med.* 2021;**6(6)**:1640–54. doi: 10.1093/jalm/jfab075, PMID 34379752. 31. Haghighat M, Browning L, Sirinukunwattana K, et al. Automated quality assessment of large digitised histology cohorts by artificial intelligence. *Sci Rep.* 2022;**12(1)**:5002. doi: 10.1038/s41598-022- 08351-5, PMID 35322056. 32. Janowczyk A, Zuo R, Gilmore H, Feldman M, Madabhushi A. HistoQC: an open-source quality control tool for digital pathology slides. *JCO Clin Cancer Inform*. 2019;**3**:1–7. doi: 10.1200/CCI.18.00157, PMID 30990737, PMCID PMC6552675.

 33. Mitchell BR, Cohen MC, Cohen S. Dealing with multi-dimensional data and the burden of annotation: easing the burden of annotation. *Am J Pathol.* 2021;**191(10)**:1709–16. doi: 10.1016/j.ajpath.2021.05.023, PMID 34129843.

 34. Sarwar S, Dent A, Faust K, et al. Physician perspectives on integration of artificial intelligence into diagnostic pathology. *NPJ Digit Med*. 2019;**2**:28. doi: 10.1038/s41746-019-0106-0, PMID 31304375.

 35. Cheng JY, Abel JT, Balis UGJ, McClintock DS, Pantanowitz L. Challenges in the development, deployment, and regulation of artificial intelligence in anatomic pathology. *Am J Pathol.* 2021;**191(10)**:1684–92. doi: 10.1016/j.ajpath.2020.10.018, PMID 33245914.

 36. Tizhoosh HR, Pantanowitz L. Artificial intelligence and digital pathology: challenges and opportunities. *J Pathol Inform*. 2018;**9**:38. doi: 10.4103/jpi.jpi_53_18, PMID 30607305.

 37. Steiner DF, Chen PC, Mermel CH. Closing the translation gap: AI applications in digital pathology. *Biochim Biophys Acta Rev Cancer*. 2021;**1875(1)**:188452. doi: 10.1016/j.bbcan.2020.188452, PMID 33065195.

 38. Sobhani F, Robinson R, Hamidinekoo A, Roxanis I, Somaiah N, Yuan Y. Artificial intelligence and digital pathology: opportunities and implications for immuno-oncology. *Biochim Biophys Acta Rev Cancer.* 2021;**1875(2)**:188520. doi: 10.1016/j.bbcan.2021.188520, PMID 33561505.

 39. Serag A, Ion-Margineanu A, Qureshi H, et al. Translational AI and deep learning in diagnostic pathology. *Front Med (Lausanne)*. 2019;**6**:185. doi: 10.3389/fmed.2019.00185, PMID 31632973.

 40. Rakha EA, Toss M, Shiino S, et al. Current and future applications of artificial intelligence in pathology: a clinical perspective*. J Clin Pathol*. 2021;**74(7)**:409–14. doi: 10.1136/jclinpath-2020-206908, PMID 32763920.

 41. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology. *Nat Rev Clin Oncol.* 2019;**16(11)**:703–15. doi: 10.1038/s41571-019-0252-y, PMID 31399699.

 42. Flach RN, Fransen NL, Sonnen AFP, et al. Implementation of artificial intelligence in diagnostic practice as a next step after going digital: the UMC Utrecht perspective. *Diagnostics (Basel).* 2022;**12(5)**:1042. doi: 10.3390/diagnostics12051042, PMID 35626198.

 43. Farris AB, Vizcarra J, Amgad M, Cooper LAD, Gutman D, Hogan J. Artificial intelligence and algorithmic computational pathology: an introduction with renal allograft examples. *Histopathology*. 2021;**78(6)**:791–804. doi: 10.1111/his.14304. PMID 33211332.

816
817 44. Kriegsmann M, Haag C, Weis CA, et al. Deep learning for the classification of small-cell and non-small-cell lung cancer. *Cancers (Basel).* 2020;**12(6)**:1604. doi: 10.3390/cancers12061604, PMID 32560475.

 45. van der Laak J, Litjens G, Ciompi F. Deep learning in histopathology: the path to the clinic. *Nat Med.* 2021;**27(5)**:775–84. doi: 10.1038/s41591-021-01343-4. PMID 33990804.

 46. Homeyer A, Lotz J, Schwen LO, et al. Artificial intelligence in pathology: from prototype to product. *J Pathol Inform.* 2021;**12**:13. doi: 10.4103/jpi.jpi_84_20, PMID 34012717.

-
-

 47. Försch S, Klauschen F, Hufnagl P, Roth W. Artificial intelligence in pathology. *Dtsch Arztebl Int.* 2021;**118(12)**:194–204. doi: 10.3238/arztebl.m2021.0011, PMID 34024323.

830 48. Kearney SJ, Lowe A, Lennerz JK, et al. Bridging the gap: the critical role of regulatory affairs and clinical affairs in the total product life cycle of pathology imaging devices and software. *Front Med (Lausanne).* 2021;**8**:765385. doi: 10.3389/fmed.2021.765385, PMID 34869473.

 49. Chauhan C, Gullapalli RR. Ethics of AI in pathology: current paradigms and emerging issues. *Am J Pathol.* 2021;**191(10)**:1673–83. doi: 10.1016/j.ajpath.2021.06.011, PMID 34252382.

 50. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. *World J Methodol.* 2021;**11(4)**:116–29. doi: 10.5662/wjm.v11.i4.116, PMID 34322364.

 51. Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. *Int J Forecast.* 1999;**15(4)**:353–75. doi: 10.1016/S0169-2070(99)00018-7.

 52. Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and Reporting Delphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. *Palliat Med.* 2017;**31(8)**:684–706. doi: 10.1177/0269216317690685, PMID 28190381.

 53. Goodman CM. The Delphi technique: a critique. *J Adv Nurs*. 1987;**12(6)**:729–34. doi: 10.1111/j.1365-2648.1987.tb01376.x, PMID 3320139.

 54. Dalkey NC, Helmer O. An experimental application of the Delphi method to the use of experts. *Manag Sci.* 1963;**9(3)**:458–67. doi: 10.1287/mnsc.9.3.458.

 55. De Vet E, Brug J, De Nooijer J, Dijkstra A, De Vries NK. Determinants of forward stage transitions: a Delphi study. *Health Educ Res.* 2005;**20(2)**:195–205. doi: 10.1093/her/cyg111, PMID 15328302.

 56. von der Gracht HA. Consensus measurement in Delphi studies. *Technol Forecast Soc Change.* 2012;**79(8)**:1525–36. doi: 10.1016/j.techfore.2012.04.013.

 57. Holmström O, Linder N, Kaingu H, et al. Point-of-care digital cytology with artificial intelligence for cervical cancer screening in a resource-limited setting. *JAMA Netw Open*. 2021;**4(3)**:e211740. doi: 10.1001/jamanetworkopen.2021.1740, PMID 33729503.

 58. Cheng S, Liu S, Yu J, et al. Robust whole slide image analysis for cervical cancer screening using deep learning. *Nat Commun.* 2021;**12(1)**:5639. doi: 10.1038/s41467-021-25296-x, PMID 34561435.

 59. Nasir-Moin M, Suriawinata AA, Ren B, et al. Evaluation of an artificial intelligence-augmented digital system for histologic classification of colorectal polyps. *JAMA Netw Open*. 2021;**4(11)**:e2135271. doi: 10.1001/jamanetworkopen.2021.35271, PMID 34792588.

 60. Iizuka O, Kanavati F, Kato K, Rambeau M, Arihiro K, Tsuneki M. Deep learning models for histopathological classification of gastric and colonic epithelial tumours. *Sci Rep*. 2020;**10(1)**:1504. doi: 10.1038/s41598-020-58467-9, PMID 32001752.

 61. Forlano R, Mullish BH, Giannakeas N, et al. High-throughput, machine learning–based quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with

 nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol.* 2020;**18(9)**:2081–2090.e9. doi: 10.1016/j.cgh.2019.12.025, PMID 31887451. 881 62. Heinemann F, Birk G, Stierstorfer B. Deep learning enables pathologist-like scoring of NASH models. *Sci Rep.* 2019;**9(1)**:18454. doi: 10.1038/s41598-019-54904-6, PMID 31804575. 63. Chatrian A, Colling RT, Browning L, et al. Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies. *Mod Pathol*. 2021;**34(9)**:1780–94. doi: 10.1038/s41379-021-00826-6, PMID 34017063. 64. Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in translational medicine and clinical practice. *Mod Pathol*. 2022;**35(1)**:23–32. doi: 10.1038/s41379-021- 00919-2, PMID 34611303. 65. Wulczyn E, Steiner DF, Moran M, et al. Interpretable survival prediction for colorectal cancer using deep learning. *NPJ Digit Med.* 2021;**4(1)**:71. doi: 10.1038/s41746-021-00427-2, PMID 33875798. 66. Sobhani F, Robinson R, Hamidinekoo A, Roxanis I, Somaiah N, Yuan Yinyin. Artificial intelligence and digital pathology: opportunities and implications for immuno-oncology. *Biochim Biophys Acta Rev Cancer.* 2021;**1875(2)**:188520, ISSN 0304-419X. doi: 10.1016/j.bbcan.2021.188520, PMID 33561505. 67. Heinz CN, Echle A, Foersch S, Bychkov A, Kather JN. The future of artificial intelligence in digital pathology – results of a survey across stakeholder groups. *Histopathology.* 2022;**80(7)**:1121–7. doi: 10.1111/his.14659, PMID 35373378. 68. Kiani A, Uyumazturk B, Rajpurkar P, et al. Impact of a deep learning assistant on the histopathologic classification of liver cancer. *NPJ Digit Med.* 2020;**3**:23. doi: 10.1038/s41746-020-0232- 8, PMID 32140566. 69. Zhou S, Marklund H, Blaha O, et al. Deep learning assistance for the histopathologic diagnosis of Helicobacter pylori. *Intell-Based Med.* 2020;1–2:(100004). doi: 10.1016/j.ibmed.2020.100004. 70. Dov D, Assaad S, Syedibrahim A, et al. A hybrid human-machine learning approach for screening prostate biopsies can improve clinical efficiency without compromising diagnostic accuracy. *Arch Pathol Lab Med.* 2022;**146(6)**:727–34. doi: 10.5858/arpa.2020-0850-OA, PMID 34591085. 71. Steiner DF, Nagpal K, Sayres R, et al. Evaluation of the use of combined artificial intelligence and pathologist assessment to review and grade prostate biopsies. *JAMA Netw Open.* 2020;**3(11)**:e2023267. doi: 10.1001/jamanetworkopen.2020.23267, PMID 33180129. 72. Murphy K, Di Ruggiero E, Upshur R, et al. Artificial intelligence for good health: a scoping review of the ethics literature. *BMC Med Ethics*. 2021;**22(1)**:14. doi: 10.1186/s12910-021-00577-8, PMID 33588803. 73. Marble HD, Huang R, Dudgeon SN, et al. A regulatory science initiative to harmonize and standardize digital pathology and machine learning processes to speed up clinical innovation to patients. *J Pathol Inform*. 2020;**11**:22. doi: 10.4103/jpi.jpi_27_20, PMID 33042601.